Mesenchymal stem cells, commonly referred to as MSCs, represent a distinct category of multipotent stromal cells that possess an impressive ability to differentiate into a diverse array of specialized cell types; these types include, but are not limited to, adipocytes, chondrocytes, and osteoblasts [[1], [2], [3]]. MSCs are isolated from diverse adult tissues, including peripheral blood, adipose tissue, bone marrow, dental pulp, dermal tissue, and others [2,[4], [5], [6]]. MSCs' potential has been extensively investigated, particularly regarding their therapeutic implications in regenerative medicine and tissue repair, as they hold promise for repairing damaged tissues and restoring function [6,7]. However, The clinical application of whole MSCs faces challenges such as low post-transplantation survival rates, immune rejection risks, and ethical concerns [8]. In response to these challenges, researchers have increasingly focused on MSC-derived extracellular vesicles, commonly abbreviated as MSC-EVs, with a particular emphasis on exosomes, a subset of these vesicles [9,10]. MSC exosomes can be characterized as nanosized vesicles secreted by MSCs, and they encapsulate a wide variety of bioactive molecules, which include essential growth factors, important cytokines, and various microRNAs that play crucial roles in cellular communication [1,3]. These bioactive molecules are capable of modulating the immune response, facilitating tissue repair processes, and exhibiting anti-inflammatory properties, making them highly valuable in therapeutic contexts [11,12]. Building on this growing interest, recent research has increasingly focused on MSC exosomes for their potential to treat a wide range of diseases, notably hematological disorders [7,13]. In contrast to whole MSCs, MSC exosomes offer distinct advantages. Their enhanced stability and resistance to degradation allow for more efficient delivery to target tissues, ensuring better therapeutic outcomes [4,14]. Additionally, MSC exosomes demonstrate reduced immunogenicity, which means they provoke a significantly lower immune response than whole MSCs, thereby minimizing the risk of immune rejection that can hinder treatment efficacy [14,15]. Moreover, MSC exosomes can be engineered to hone in on specific cell types or particular tissues, thereby enhancing the therapeutic efficacy of the treatment provided [1]. Another significant benefit of MSC exosomes lies in their scalability; they can be produced in substantial quantities, rendering them suitable for various clinical applications where large doses may be required [2]. In the realm of hematological disorders, MSC exosomes have exhibited encouraging therapeutic effects, as evidenced by numerous preclinical and clinical studies that have highlighted their capabilities [1]. These exosomes have been shown to modulate the tumor microenvironment effectively, suppress tumor growth, and significantly enhance the efficacy of conventional therapies employed to treat such disorders [16]. They also support blood cell production, speed up tissue repair, and reduce inflammation, offering a comprehensive treatment strategy [2,17,18]. To bridge the gap between emerging basic science and clinical application, this review examines the current understanding of MSC exosomes and their potential as targeted therapies for hematological disorders. By delving into the exciting potential of MSC exosomes, we aspire to illuminate a novel approach to the treatment of hematological diseases, ultimately pointing toward enhancing patient outcomes and improving the quality of care provided.